ID | 48855 |
フルテキストURL | |
著者 |
Huang, P
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaku, H
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
publons
Chen, J
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kashiwakura, Y
Innovation Center Okayama for Nanobio-Targeted Therapy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Saika, T
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Nasu, Y
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
publons
researchmap
Urata, Y
Oncolys BioPharma Inc.
Fujiwara, T
Center for Gene and Cell Therapy, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
ORCID
Kaken ID
publons
researchmap
Watanabe, M
Department of Urology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences
Kaken ID
publons
researchmap
|
抄録 | OBP-301 (a telomerase-specific, replication-competent adenovirus with hTERT promoter) was constructed in a previous study and it showed a strong anticancer effect by inducing cell lysis in human lung and prostate cancer cells. This study investigated the effectiveness of a combination therapy of OBP-301 and interleukin-2 (IL-2) in a mouse model of renal cell carcinoma (RCC). The cell-killing effect of OBP-301 was confirmed in vitro in the RENCA cancer cells. In in vivo experiment, luciferase-expressing RENCA cells were implanted in the left kidney and lung of BALB/c mice to prepare the RCC metastatic model. The animals were randomly divided into four treatment groups: PBS, IL-2 alone, OBP-301 alone and the combination. The analyses of orthotopic tumor weight, lung metastasis and luciferin-stained tumor images 14 days after each treatment showed significant tumor growth inhibition in the combination group in comparison with that in the OBP-301- or IL-2-treated groups. In addition, the percentage of regulatory T-cells (Tregs) in the combination group was significantly suppressed in comparison with that in the PBS and single-agent treatment groups. The outcomes of this study suggest that tumor-specific oncolytic immunovirotherapy may become an attractive strategy for the treatment of human RCC.
|
キーワード | renal cell carcinoma
OBP-301
adenovirus
hTERT
interleukin-2
|
発行日 | 2010-07
|
出版物タイトル |
Cancer Gene Therapy
|
巻 | 17巻
|
号 | 7号
|
出版者 | Nature Publishing Group
|
開始ページ | 484
|
終了ページ | 491
|
ISSN | 0929-1903
|
NCID | AA12570566
|
資料タイプ |
学術雑誌論文
|
プロジェクト |
ナノバイオ標的医療の融合的創出拠点
|
オフィシャル URL | http://www.nature.com/cgt/journal/v17/n7/full/cgt20105a.html
|
言語 |
英語
|
著作権者 | © Nature Publishing Group
|
論文のバージョン | author
|
査読 |
有り
|
DOI | |
PubMed ID | |
Web of Science KeyUT |